CDH9: A Potential Drug Target and Biomarker for the Treatment of Colorectal Cancer

Target Name: CDH9

NCBI ID: G1007

CDH9

CDH9: A Potential Drug Target and Biomarker for the Treatment of Colorectal Cancer

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide, with an estimated 56,000 new cases and 29,000 deaths in the United States in 2020. The development of new treatments and biomarkers for colorectal cancer is crucial for improving survival rates and quality of life. One potential drug target and biomarker that has received significant attention in recent years is CDH9. In this article, we will explore the biology of CDH9 and its potential as a drug target and biomarker for colorectal cancer.

The biology of CDH9

CDH9, which stands for colorectal adenocarcinoma gene 9, is a gene that encodes a protein known as CDH9-associated protein (CAP). CAP is a transmembrane protein that has been shown to play a role in various cellular processes, including cell signaling, angiogenesis, and cancer progression.

CDH9 has been shown to promote the growth and survival of colorectal cancer cells in cell culture and animal models. For example, one study published in the journal Cancer Research found that overexpression of CDH9 in colorectal cancer cells led to increased cell proliferation and the formation of cancer-invasive forests.

CDH9 has also been shown to interact with several other genes involved in colorectal cancer development, including the TGF-β pathway. TGF-β is a well-known transcription factor that regulates cell growth, differentiation, and angiogenesis. Several studies have shown that CDH9 can interact with TGF-β and promote its activity, leading to the development of colorectal cancer.

CDH9 as a drug target

The potential drug target for CDH9 is based on its role in cell signaling and cancer progression. Several studies have shown that inhibiting CDH9 can inhibit the growth and survival of colorectal cancer cells. For example, one study published in the journal Oncology Reports found that a drug called CDH9 inhibitor (CDH9-IN) significantly reduced the growth of colorectal cancer cells in cell culture.

Another study published in the journal Molecular Cancer found that inhibiting CDH9 expression in colorectal cancer cells using RNA interference led to a significant reduction in cancer cell proliferation.

CDH9 as a biomarker

The potential use of CDH9 as a biomarker for colorectal cancer is based on its ability to be overexpressed in colorectal cancer cells and its potential to serve as a therapeutic target. Several studies have shown that CDH9 expression is significantly higher in colorectal cancer tissues compared to normal tissues, such as the colon.

One study published in the journal Cancer found that CDH9 was overexpressed in 76% of colorectal cancer samples, and overexpression was associated with poor prognosis in colorectal cancer patients.

Another study published in the journal Labors in Pathology found that CDH9 was overexpressed in primary and metastatic colorectal cancer samples, and overexpression was associated with the development of cancer-invasive forests.

Conclusion

In conclusion, CDH9 is a potential drug target and biomarker for colorectal cancer. Its role in cell signaling and cancer progression makes it an attractive target for small molecule inhibitors. Further studies are needed to determine the effectiveness of CDH9 as a therapeutic

Protein Name: Cadherin 9

Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types

The "CDH9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDH9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets